Associations of matrix metalloproteinase (MMP)-8, MMP-9, and their inhibitor, tissue inhibitor of metalloproteinase-1, with obesity-related biomarkers in apparently healthy adolescent boys

Youn Ho Shin, MD1,2, Ki Eun Kim, MD1, Yong-Jae Lee, MD, MPH, PhD3, Jae-Hwan Nam, PhD4, Young Mi Hong, MD, PhD5, Hye-Jung Shin, MD6

1Department of Pediatrics, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, 2Department of Medicine, The Graduate School, Yonsei University, Seoul, 3Department of Family Medicine, Yonsei University College of Medicine, Seoul, 4Department of Biotechnology, The Catholic University of Korea, Bucheon St. Mary’s Hospital, Bucheon, 5Department of Pediatrics, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, 6Department of Pediatrics, National Medical Center, Seoul, Korea

Purpose: Matrix metalloproteinases (MMPs) have been implicated in atherosclerosis, and therefore, are considered risk factors for metabolic dysfunction in adults. However, there is little data on circulating levels of MMPs and tissue inhibitors of MMPs (TIMPs) with regard to obesity-related biomarkers in the general adolescent population. In the present study, we determined the associations of MMP-8, MMP-9, and TIMP-1 levels and MMP-8/TIMP-1 and MMP-9/TIMP-1 ratios with obesity-related biomarkers in apparently healthy adolescent boys.

Methods: We measured MMP and TIMP concentrations in plasma samples using the enzyme-linked immunosorbent assay and analyzed their associations with obesity-related biomarkers, such as liver enzymes and lipid profiles, in a sample of 91 Korean boys aged 13–14 years who participated in a general health check-up.

Results: The mean age of the boys was 13.8±0.3 years; 72 boys were normal weight and 19 were overweight/obese. The Pearson correlation coefficients revealed a significant correlation between MMP-8 and aspartate aminotransferase ($r=0.217$, $P=0.039$) and alanine aminotransferase ($r=0.250$, $P=0.017$) and between TIMP-1 and aspartate aminotransferase ($r=0.267$, $P=0.011$). In a multivariate linear regression analysis, serum alanine aminotransferase was positively associated with the MMP-8 level. There were no significant differences in the MMP-8, MMP-9, and TIMP-1 levels or MMP-8/TIMP-1 and MMP-9/TIMP-1 ratios between control and overweight/obese subjects.

Conclusion: We found a significant association between the MMP-8 level and alanine aminotransferase in the apparently healthy adolescent boys. These findings indicate that there may be a pathophysiological mechanism underlying the relationship between MMP-8 and liver enzymes in young adolescents.

Key words: Adolescent, Alanine aminotransferase, Overweight, Matrix metalloproteinases, Tissue inhibitor of metalloproteinase

Introduction

Obesity has become a large public health concern and is now occurring at younger ages worldwide1. Compelling evidence suggests that childhood overweight and obesity often persist into adulthood and is associated with increased morbidity and mortality...
in adulthood. This metabolic disorder increases the risk of cardiovascular diseases, ultimately causing premature death. Studies have suggested that adipocytes not only store fat, but are also an active endocrine and paracrine organ that releases various bioactive mediators that influence body weight homeostasis, insulin resistance, circulating lipid levels, arterial blood pressure (BP), and coagulation.

A growing body of research into the role of adipocytes also suggests that they play an important role in inflammatory mechanisms, leading to the development of atherosclerosis. Atherosclerosis is characterized by vascular remodeling and accumulation of lipids and fibrous elements in the large arteries. Several members of the matrix metalloproteinase (MMP) family and their endogenous inhibitors, the tissue inhibitors of MMPs (TIMPs), have been suggested to be primary mediators of vascular remodeling. Therefore, a critical equilibrium between MMPs and TIMPs must exist to retain cardiovascular integrity and to prevent the development of cardiovascular diseases.

Laboratory and clinical studies have reported that modified expression or activity of MMPs, TIMPs, or both is essential in the pathophysiology of various cardiovascular diseases and obesity. Despite mounting evidence that MMPs and TIMPs play a role in the pathophysiology of cardiovascular diseases and obesity, no previous work has studied the relationships of circulating concentrations of MMP-8, MMP-9, and TIMP-1 levels and their ratios with obesity-related biomarkers in the general population of adolescents. Understanding these relationships could help determine if atherosclerosis develops early in childhood and gradually accelerates during adolescence in obese children, as has been previously suggested.

Therefore, the aim of the present study was to determine the relationships of MMP-8, MMP-9, and TIMP-1 levels and the MMP-8/TIMP-1 and MMP-9/TIMP-1 ratios with anthropometric measures and obesity-related biomarkers, such as liver enzymes and lipid profiles, in apparently healthy adolescent boys.

After these exclusions, 91 subjects (all boys) were included in our analysis. Health examinations were performed by a single physician according to a standardized procedure. Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with an automatic height–weight scale while subjects wore light indoor clothing and no shoes. BMI was calculated as weight (kg)/height (m²). The BMI percentiles for age and sex were determined according to the 2007 Korea Growth Charts in order to determine normal-weight, overweight, and obesity. The subjects were subdivided into two groups according to their BMI value: the normal subgroup (BMI<85th percentile) and the overweight/obese subgroup (BMI≥85th percentile). A certified technician measured BP a maximum of three times on the right arm in seated subjects after a 5-minute rest using an automatic BP recorder. The institutional review board approved the study, and written informed consent was obtained from the subjects or their guardians.

2. Laboratory analyses for obesity-related biomarkers

Following a 12-hour overnight fast, blood samples were obtained from the antecubital vein of each subject by venipuncture and were immediately centrifuged, aliquoted, and frozen at −20°C. The frozen serum and plasma samples were stored at −80°C until analysis. Fasting plasma glucose (FPG), total cholesterol, triglyceride, and high-density lipoprotein cholesterol (LDL-C) levels were measured using enzymatic methods using a Hitachi 7600–110 automated chemistry analyzer (Hitachi, Tokyo, Japan). Levels of low-density lipoprotein cholesterol (LDL-C) were calculated using the following formula: LDL-C=total cholesterol−HDL-C−(triglyceride/5). Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured. Fasting insulin levels were measured by an electroluminescence immunoassay (Roche, Indianapolis, IN, USA). Insulin resistance was estimated using the homeostatic model assessment of insulin resistance (HOMA-IR) and calculated using the following formula: HOMA-IR=[fasting insulin (µIU/mL)×fasting glucose (mg/dL)/18]/22.5.

3. Plasma MMPs and TIMPs measurement

Concentrations of MMP-8, MMP-9, and TIMP-1 were measured in plasma using commercially available enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

4. Statistical analysis

All continuous variables are presented as mean with standard deviation or are shown as scatter plots. The Mann-Whitney U test or the Kruskal-Wallis test was used to examine statistical differences between groups. The Pearson correlation analyses were used to calculate the correlation between plasma MMP or...
TIMP levels and anthropometric measures and obesity-related biomarkers. To examine independent correlates of plasma MMP-8 levels, a multivariate linear regression analysis was conducted with the MMP-8 level as the dependent variable. All analyses were conducted by using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA). All statistical tests were two-sided, and \( P<0.05 \) represented statistical significance.

### Results

#### 1. Population characteristics

The demographic and clinical characteristics of the study population are presented in Table 1. All subjects were boys, and the mean age was 13.8±0.3 years. The mean clinical and laboratory values were within the normal ranges. Seventy-two subjects were normal-weight and nineteen subjects were overweight (16 subjects) or obese (3 subjects).

#### 2. Comparison of clinical and laboratory parameters between control and overweight/obese subjects

Table 2 compares the clinical and laboratory parameters for control (n=72) and overweight/obese subjects (n=19). BMI, ALT, LDL-cholesterol, and HOMA-IR were significantly higher and HDL-C was significantly lower in the overweight/obese subjects. There were no significant differences in age, systolic and diastolic BP, AST, total cholesterol, triglyceride, fasting glucose, or high sensitivity C-reactive protein between groups.

#### 3. Comparison of MMPs, TIMPs, and their ratios between control and overweight/obese subjects

Table 3 compares MMPs, TIMPs, and their ratios for control and overweight/obese subjects. There were no significant differences in MMP or TIMP concentrations or their ratios between groups.

#### 4. Associations of MMP-8, MMP-9, and TIMP-1 levels, and MMP-8/TIMP-1, and MMP-9/TIMP-1 ratios with anthropometric measures and obesity-related biomarkers

The Pearson correlation results between MMP-8, MMP-9, and TIMP-1 levels, and the MMP-8/TIMP-1 ratios and various parameters are listed in Table 4. The MMP-8 level was significantly correlated with AST (\( r=0.217, P=0.039 \)) and ALT (\( r=0.250, P=0.017 \)) (Figs. 1, 2; Table 4). The TIMP-1

### Table 1. General characteristics of the study subjects

| Characteristic            | All subjects (n=91) |
|---------------------------|---------------------|
| Male sex                  | 91                  |
| Age (yr)                  | 13.8±0.3            |
| Body mass index (kg/m²)   | 21.1±3.2            |
| Systolic BP (mmHg)        | 107.4±12.5          |
| Diastolic BP (mmHg)       | 53.9±7.5            |
| Aspartate aminotransferase (IU/L) | 23.2±6.0          |
| Alanine aminotransferase (IU/L) | 16.4±9.1       |
| Total cholesterol (mg/dL) | 149.2±33.2          |
| HDL cholesterol (mg/dL)   | 52.6±10.7           |
| LDL cholesterol (mg/dL)   | 88.3±25.8           |
| Triglyceride (mg/dL)      | 68.0±38.0           |
| Fasting glucose (mg/dL)   | 98.5±6.9            |
| HOMA-IR                   | 2.4±1.8             |
| hs-CRP (mg/dL)            | 0.9±1.2             |

Values are presented as mean±standard deviation. HDL cholesterol, high density lipoprotein-cholesterol; LDL cholesterol, low density lipoprotein-cholesterol; HOMA-IR, homeostasis model of assessment insulin resistance; hs-CRP, high sensitivity C-reactive protein.

### Table 2. Comparison of anthropometric and laboratory parameters in the control and overweight/obese subjects

| Variable                        | Control subjects (n=72) | Overweight/obese subjects (n=19) | P value |
|---------------------------------|------------------------|----------------------------------|---------|
| Age (yr)                        | 13.8±0.3               | 13.7±0.4                         | 0.233   |
| Body mass index (kg/m²)         | 19.9±2.1               | 25.8±2.2                         | <0.001  |
| Systolic BP (mmHg)              | 106.9±13.4             | 109.5±8.1                        | 0.287   |
| Diastolic BP (mmHg)             | 53.0±6.5               | 57.1±10.0                        | 0.137   |
| Aspartate aminotransferase (IU/L) | 22.7±4.7              | 25.3±9.4                         | 0.691   |
| Alanine aminotransferase (IU/L) | 14.8±7.2              | 22.3±12.7                        | 0.001   |
| Total cholesterol (mg/dL)       | 150.0±30.2             | 146.2±43.6                       | 0.903   |
| HDL cholesterol (mg/dL)         | 53.9±10.5              | 48.0±10.2                        | 0.011   |
| LDL cholesterol (mg/dL)         | 85.9±24.8              | 97.2±28.2                        | 0.040   |
| Triglyceride (mg/dL)            | 67.3±39.0              | 70.7±34.3                        | 0.372   |
| Fasting glucose (mg/dL)         | 98.5±7.1               | 98.5±6.1                         | 0.992   |
| HOMA-IR                         | 2.1±1.6                | 3.3±2.3                          | 0.001   |
| hs-CRP (mg/dL)                  | 0.9±1.3                | 1.0±1.0                          | 0.111   |

Values are presented as mean±standard deviation. HDL cholesterol, high density lipoprotein-cholesterol; LDL cholesterol, low density lipoprotein-cholesterol; HOMA-IR, homeostasis model of assessment insulin resistance; hs-CRP, high sensitivity C-reactive protein.

### Table 3. Comparison of MMPs, TIMPs, and their ratios in the control and overweight/obese subjects

| Variable                        | Control subjects (n=72) | Overweight/obese subjects (n=19) | P value |
|---------------------------------|------------------------|----------------------------------|---------|
| MMP-8 (ng/mL)                   | 8.1±4.5                | 9.7±11.4                         | 0.830   |
| MMP-9 (ng/mL)                   | 126.7±90.6             | 139.7±132.8                      | 0.646   |
| TIMP-1 (ng/mL)                  | 192.3±42.2             | 186.3±44.9                       | 0.612   |
| MMP-8/TIMP-1                    | 0.044±0.024            | 0.049±0.042                      | 0.815   |
| MMP-9/TIMP-1                    | 0.664±0.445            | 0.718±0.506                      | 0.519   |

Values are presented as mean±standard deviation. MMP, matrix metalloproteinase; TIMP, tissue inhibitor of matrix metalloproteinase.
level was significantly correlated with AST \(r=0.267, P=0.011\) (Fig. 3, Table 4). There were no significant correlations between MMP-8, MMP-9, and TIMP-1 levels, or their ratios and the other clinical parameters. In the multivariate linear regression, ALT was positively associated with MMP-8 levels (Table 5). There were no significant differences between MMP-8, MMP-9, and TIMP-1 levels, or MMP-8/TIMP-1 and MMP-9/TIMP-1 ratios across serum AST and ALT quartiles (data not shown).

**Discussion**

The aim of the present study was to determine the relationships of MMP-8, MMP-9, and TIMP-1 levels, and the MMP-8/TIMP-1 and MMP-9/TIMP-1 ratios with anthropometric measures and obesity-related biomarkers, such as liver enzymes and lipid profiles, in apparently healthy adolescent boys. The prevalence of overweight, obesity, and metabolic syndrome is increasing in Korea and around the world. Despite intense research, the pathogenesis and pathophysiology of these complex diseases are not well understood. In recent years, studies have shown that obese children and adolescents have higher circulating MMP-8 concentrations, lower TIMP-1 levels, and significant correlations with liver enzyme activities.
has been regarded as the hepatic manifestation of overweight\textsuperscript{21}, obesity\textsuperscript{22}, and metabolic syndrome\textsuperscript{22-24}. Although liver biopsy is the gold standard for identifying NAFLD, serum biomarkers, notably ALT level, have been shown to be sensitive in diagnosing NAFLD. These biomarkers are also associated with increased risk of overweight, obesity, metabolic syndrome, diabetes mellitus, and cardiovascular disease\textsuperscript{24-26}. Recent studies have reported that liver enzymes increase before non-alcoholic fatty liver develops, suggesting that liver enzymes may be a marker of NAFLD\textsuperscript{19,22-24,27,28}. Although we did not perform a liver biopsy study, we found that the serum MMP-8 level was positively associated with the ALT level using the multivariate linear regression model.

Why MMP-8, also known as neutrophil collagenase or collagenase-2, is positively correlated with liver enzymes remains unclear. One possible explanation for the association between MMP-8 and ALT is that MMP-8 produced by neutrophils and endothelial cells may be involved in collagen breakdown, leading to increased vulnerability to atherosclerotic plaques\textsuperscript{21,29}. The MMP-8 level has been shown to be positively associated with subclinical and clinical atherosclerosis\textsuperscript{22-24}, thus, the MMP-8 concentration has been proposed as a marker of atherosclerosis. Atherosclerosis begins early in life\textsuperscript{22} and gradually accelerates throughout adolescence in children with risk factors\textsuperscript{13}. A cross-sectional study of 830 healthy adults with normal ALT levels showed that 48.4\% of men and 36.7\% of women had liver steatosis as determined by ultrasonography\textsuperscript{44}. In women, the carotid intima-media thickness increased significantly with increasing quartiles of ALT levels\textsuperscript{44}. These results suggest that increased ALT level, even within the reference range, is closely correlated with atherosclerotic changes in healthy adults\textsuperscript{44}. Although we did not perform ultrasonography, the subjects with elevated liver enzymes in our study may have already had fatty deposits in their vessels, thereby resulting in a positive association between liver enzymes and MMP-8 concentrations. Another possible explanation for the association between MMP-8 and ALT is as follows: the liver has a rich blood supply, as indicated by its dark red or reddish brown color and the blood vessels are lined with endothelial cells, which produce MMP-8 in the presence of fibrinolytic changes. Thus, liver damage due to hepatic metabolic overload may cause blood vessels to become disorganized, inducing endothelial cells that line the vessels to overproduce MMP-8\textsuperscript{40}.

The present study has some limitations. First, this study used a cross-sectional design; therefore, the causality of the association between MMP-8 levels and liver enzymes remains uncertain. However, we speculate that, since MMP has fibrinolytic properties, it may have a significant role in liver metabolism, thereby resulting in elevated liver enzymes. Second, we did not measure other liver enzymes, such as γ-glutamyl transferase and alkaline
phosphatase, which are often used as diagnostic markers for liver diseases. Finally, we did not perform ultrasonography on subjects with elevated AST and ALT in order to diagnose NAFLD.

In conclusion, we found evidence of significant positive associations between MMP-8 and TIMP-1 levels and liver enzymes in a general population of apparently healthy adolescent boys. Further research with larger sample sizes is warranted to determine if a pathophysiological mechanism is involved in the associations between MMPs and TIMPs and liver enzymes.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This study was supported by a 2011 research grant from the Korean Pediatric Society (MSD Award).

References

1. Huffman MD, Capewell S, Ning H, Shay CM, Ford ES, Lloyd-Jones DM. Cardiovascular health behavior and health factor changes (1988–2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. Circulation 2012;125:2595-602.

2. Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int J Obes (Lond) 2011;35:891-8.

3. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Rev 2014;30:447-56.

4. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-80.

5. Wu G, Li H, Zhou M, Fang Q, Bao Y, Xu A, et al. Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding protein linking obesity and atherosclerosis. Diabetes Metab Res Rev 2014;30:447-56.

6. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.

7. Beaudoux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004;42:121-31.

8. Zayani Y, Allal-Elasmi M, Jacob MP, Zidi W, Zaroui A, Feki M, et al. Peripheral blood levels of matrix and inflammatory mediators are elevated in Tunisian patients with acute coronary syndromes. Clin Lab 2013;59:169-75.

9. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008;41:875-80.

10. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198:320-31.

11. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005;69:1035-40.

12. Huang HL, Wu S, Hsu LA, Teng MS, Lin JF, Sun YC, et al. Genetic variants associated with circulating MMP1 levels near matrix metalloproteinase genes on chromosome 11q21-22 in Taiwanese: interaction with obesity. BMC Med Genet 2013;14:30.

13. Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Bioch 2009;42:984-90.

14. Belo VA, Luizon MR, Carneiro PC, Gomes VA, Lacchini R, Lanna CM, et al. Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. Mol Biol Rep 2013;40:2697-704.

15. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr 2008;51:1-25.

16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

17. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2007;193:438-44.

18. Jang M, Berry D. Overweight, obesity, and metabolic syndrome in adults and children in South Korea: a review of the literature. Clin Nurs Res 2011;20:276-91.

19. Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World J Gastroenterol 2012;18:3775-81.

20. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999–2004. Gastroenterology 2007;133:1814-20.

21. Kodhelaj K, Resuli B, Petrela E, Malaj V, Jaze H. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children. Minerva Pediatr 2014;66:23-30.

22. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203.

23. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol 2010;4:623-35.

24. Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. World J Gastroenterol 2010;16:5280-5.

25. Goessling W, Massaro JM, Vasan RS, D’Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008;135:1935-44, 1944.e1.

26. Gonzalez-Gil EM, Bueno-Lozano G, Bueno-Lozano O, Moreno LA, Cuadron-Andres I, Huerta-Blas P, et al. Serum transaminases concentrations in obese children and adolescents. J Physiol Biochem 2009;65:51-9.

27. Abe Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Ogawa Y, et al.
Usefulness of GPT for diagnosis of metabolic syndrome in obese Japanese children. J Atheroscler Thromb 2009;16:902-9.

28. Calcaterra V, Muratori T, Klersy C, Albertini R, Caramagna C, Brizzi V, et al. Early-onset metabolic syndrome in prepubertal obese children and the possible role of alanine aminotransferase as marker of metabolic syndrome. Ann Nutr Metab 2011;58:307-14.

29. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899-904.

30. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006;187:161-9.

31. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007;27:2722-8.

32. McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HC Jr, et al. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 2006;118:1447-55.

33. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6.

34. Kim SK, Kim DJ, Kim SH, Lee YK, Park SW, Cho YW, et al. Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis. Diabetes Res Clin Pract 2010;98:111-6.

35. Fang C, Wen G, Zhang L, Lin L, Moore A, Wu S, et al. An important role of matrix metalloproteinase-8 in angiogenesis in vitro and in vivo. Cardiovasc Res 2013;99:146-55.